Nutex Health (NUTX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for 2025 reached $875.3 million, an 82% increase from $479.9 million in 2024 [5][22] - Net income increased to $70.8 million compared to $52.1 million in 2024 [5][28] - Adjusted EBITDA rose to $259.6 million, up 152.6% from $102.8 million in 2024 [6][29] - Cash on hand grew to $186 million as of December 31, 2025, up from $41 million a year earlier [8][42] Business Line Data and Key Metrics Changes - Hospital division revenue was $844.2 million in 2025, with mature hospitals increasing revenue by 73.4% [22][24] - Total patient visits increased to 188.3 thousand, an 11.8% rise from 168.4 thousand in 2024 [7][24] - Population health division revenue grew slightly by 0.7% to $31 million in 2025 [24] Market Data and Key Metrics Changes - The company reported a decrease in the current portion of long-term debt from $14.4 million to $13.3 million, while net long-term debt increased from $22.5 million to $29.2 million [8] - The ineligible claim submission rate for Nutex Health is approximately 8%, significantly better than the national average of 19% [10][38] Company Strategy and Development Direction - The company is focused on four priority areas: share repurchases, growth at existing hospitals, expansion of the Independent Physician Association (IPA), and real estate development strategy [15][18] - Nutex Health plans to open new hospitals in Jacksonville, West Little Rock, and San Antonio in 2026, with additional facilities planned for 2027 and 2028 [19][71] - The company aims to enhance its operational infrastructure to support higher throughput and a more diversified patient mix [49][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate regulatory challenges and optimize the Independent Dispute Resolution (IDR) process [20][63] - The company is optimistic about its growth trajectory entering 2026, supported by strong liquidity and operational improvements [20][42] Other Important Information - The company recognized a one-time $55 million revenue reduction related to arbitration claims deemed ineligible [9][30] - Total stock compensation expense for 2025 was $117 million, a significant increase from $16.6 million in 2024 [26] Q&A Session Summary Question: IDR-related submission rates and collection rates - The company noted a shift in IDR submission rates from 60%-70% to 50%-60%, with improved collection rates around 85% [56][60] - Management indicated that fewer submissions may reflect higher quality claims leading to better collections [62][65] Question: Reopening of a hospital in Texas - The decision to reopen was based on improved reimbursement through the IDR process and increased volume expectations [67][68] - Management confirmed they remain on track to open 5 to 6 facilities in 2026 and discussed a new real estate strategy to support this [71][72] Question: Timing of learning about the true-up adjustment - The company learned about the true-up adjustment in the middle of the fourth quarter, which was new information that required analysis before communication [77][79]